Business Description
Reata Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75615P1030
Share Class Description:
RETA: Class ADescription
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.99 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 1.9 | |||||
| Debt-to-EBITDA | -3.61 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 5.73 | |||||
| Beneish M-Score | 34.23 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -58.8 | |||||
| 3-Year EBITDA Growth Rate | 6.9 | |||||
| 3-Year EPS without NRI Growth Rate | 3.6 | |||||
| 3-Year FCF Growth Rate | 12 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 90.33 | |||||
| 9-Day RSI | 87.67 | |||||
| 14-Day RSI | 84.64 | |||||
| 6-1 Month Momentum % | 97.22 | |||||
| 12-1 Month Momentum % | 635.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.21 | |||||
| Quick Ratio | 3.19 | |||||
| Cash Ratio | 2.64 | |||||
| Days Inventory | 1269.3 | |||||
| Days Sales Outstanding | 352.27 | |||||
| Days Payable | 5892.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.4 | |||||
| Shareholder Yield % | 0.1 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.4 | |||||
| Operating Margin % | -1455.08 | |||||
| Net Margin % | -373.17 | |||||
| FCF Margin % | -1062.39 | |||||
| ROA % | -16.31 | |||||
| ROIC % | -228.72 | |||||
| ROC (Joel Greenblatt) % | -39.23 | |||||
| ROCE % | -10.01 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 303.45 | |||||
| PB Ratio | 74.74 | |||||
| Price-to-Tangible-Book | 74.61 | |||||
| EV-to-EBIT | -136.03 | |||||
| EV-to-EBITDA | -139.38 | |||||
| EV-to-Revenue | 272.66 | |||||
| EV-to-FCF | -25.66 | |||||
| Earnings Yield (Greenblatt) % | -0.74 | |||||
| FCF Yield % | -3.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RETA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Reata Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 23.481 | ||
| EPS (TTM) ($) | -2.98 | ||
| Beta | 0 | ||
| Volatility % | 196.64 | ||
| 14-Day RSI | 84.64 | ||
| 14-Day ATR ($) | 0.865062 | ||
| 20-Day SMA ($) | 171.0145 | ||
| 12-1 Month Momentum % | 635.74 | ||
| 52-Week Range ($) | 21.83 - 172.46 | ||
| Shares Outstanding (Mil) | 38.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Reata Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Reata Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Reata Pharmaceuticals Inc Frequently Asked Questions
What is Reata Pharmaceuticals Inc(RETA)'s stock price today?
The current price of RETA is $172.36. The 52 week high of RETA is $172.46 and 52 week low is $21.83.
When is next earnings date of Reata Pharmaceuticals Inc(RETA)?
The next earnings date of Reata Pharmaceuticals Inc(RETA) is 2024-05-10 Est..
Does Reata Pharmaceuticals Inc(RETA) pay dividends? If so, how much?
Reata Pharmaceuticals Inc(RETA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers